重视肝纤维化的诊治

郭津生

doi:10.3969/j.issn.1001-5256.2018.01.002

重视肝纤维化的诊治

DOI: 10.3969/j.issn.1001-5256.2018.01.002

郭津生

复旦大学附属中山医院消化科

详细信息

中图分类号: R575.2
计量
- 文章访问数: 2576
- HTML全文浏览量: 44
- PDF下载量: 577
- 被引次数: 0
出版历程
- 出版日期: 2018-01-20

The critical importance of diagnosing and treating liver fibrosis

Guo JinSheng

Department of Gastroenterology, Zhongshan Hospital, Fudan University, Shanghai 200032, China

摘要

摘要: 肝纤维化是各种病因引起慢性反复肝损伤后的疤痕修复反应,是肝硬化发生的早期、可逆阶段。概述了肝纤维化与肝硬化的区别和慢性肝病的分期方法,重点论述了肝纤维化早期诊治的重要性,介绍了目前早期诊断评估方法以及肝纤维化的药物开发与治疗进展。强调肝纤维化患者的诊断及治疗对防止肝病进展为失代偿期肝硬化具有重要意义。
- 肝硬化 /
- 诊断 /
- 治疗
Abstract: Liver fibrosis is the scar repairing reaction in response to chronic liver injury due to various etiologies. It has been considered as the early and reversible stage of liver cirrhosis. This article points out the distinction between liver fibrosis and cirrhosis, introduces the current staging system of chronic liver diseases, and recent progress in diagnosing and evaluating liver fibrosis, as well as the medical treatment.The critical importance of diagnosing and treating liver fibrosis in preventing liver diseases progression into decompensated liver cirrhosis is emphasized.
- liver cirrhosis /
- diagnosis /
- therapy

HTML全文

参考文献(22)

[1]EL-SERAG HB.Epidemiology of viral hepatitis and hepatocellular carcinoma[J].Gastroenterology, 2012, 142 (6) :1264-1273.

[2]TORRE LA, BRAY F, SIEGEL RL, et al.Global cancer statistics, 2012[J].CA Cancer J Clin, 2015, 65 (2) :87-108.

[3]GARCIA-TSAO G, FRIEDMAN S, IREDALE J, et al.Now there are many (stages) where before there was one:in search of a pathophysiological classification of cirrhosis[J].Hepatology, 2010, 51 (4) :1445-1449.

[4]AUGUSTIN S, PONS M, MAURICE JB, et al.Expanding the Baveno VI criteria for the screening of varices in patients with compensated advanced chronic liver disease[J].Hepatology, 2017, 66 (6) :1980-1988.

[5]de FRANCHIS R, Baveno VI Faculty.Expanding consensus in portal hypertension:report of the Baveno VI Consensus Workshop:stratifying risk and individualizing care for portal hypertension[J].J Hepatol, 2015, 63 (3) :743-752.

[6]CHANG TT, LIAW YF, WU SS, et al.Long-term entecavir therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis B[J].Hepatology, 2010, 52 (3) :886-893.

[7]WONG GL, CHAN HL, MAK CW, et al.Entecavir treatment reduces hepatic events and deaths in chronic hepatitis B patients with liver cirrhosis[J].Hepatology, 2013, 58 (5) :1537-1547.

[8]BEDOSSA P, DARGERE D, PARADIS V.Sampling variability of liver fibrosis in chronic hepatitis C[J].Hepatology, 2003, 38 (6) :1449-1457.

[9]TAPPER EB, CASTERA L, AFDHAL NH.Fibro Scan (vibration-controlled transient elastography) :where does it stand in the United States practice[J].Clin Gastroenterol Hepatol, 2015, 13 (1) :27-36.

[10]LIM JK, FLAMM SL, SINGH S, et al.American Gastroenterological Association Institute Guideline on the role of elastography in the evaluation of liver fibrosis[J].Gastroenterology, 2017, 152 (6) :1536-1543.

[11]SHIHA G, IBRAHIM A, HELMY A, et al.Asian-Pacific Association for the Study of the Liver (APASL) consensus guidelines on invasive and non-invasive assessment of hepatic fibrosis:a 2016update[J].Hepatol Int, 2017, 11 (1) :1-30.

[12]FRIEDRICH-RUST M, POYNARD T, CASTERA L.Critical comparison of elastography methods to assess chronic liver disease[J].Nat Rev Gastroenterol Hepatol, 2016, 13 (7) :402-411.

[13]TOROK NJ, DRANOFF JA, SCHUPPAN D, et al.Strategies and endpoints of antifibrotic drug trials:summary and recommendations from the AASLD Emerging Trends Conference, Chicago, June 2014[J].Hepatology, 2015, 62 (2) :627-634.

[14]WANG Y, LIANG X, YANG J, et al.Improved performance of quantitative collagen parameters versus standard histology in longitudinal assessment of non-advanced liver fibrosis for chronic hepatitis B[J].J Viral Hepat, 2017.[Epub ahead of print]

[15]WANG Y, VINCENT R, YANG J, et al.Dual-photon microscopy-based quantitation of fibrosis-related parameters (q-FP) to model disease progression in steatohepatitis[J].Hepatology, 2017, 65 (6) :1891-1903.

[16] GE PS, RUNYON BA.Treatment of patients with cirrhosis[J].N Engl J Med, 2016, 375 (8) :767-777.

[17]ROCKEY DC.Translating an understanding of the pathogenesis of hepatic fibrosis to novel therapies[J].Clin Gastroenterol Hepatol, 2013, 11 (3) :224-231.

[18]FRIEDMAN SL, RATZIU V, HARRISON SA, et al.A randomized, placebo-controlled trial of cenicriviroc for treatment of nonalcoholic steatohepatitis with fibrosis[J].Hepatology, 2017.[Epub ahead of print]

[19]TRAUTWEIN C, FRIEDMAN SL, SCHUPPAN D, et al.Hepatic fibrosis:concept to treatment[J].J Hepatol, 2015, 62 (1 Suppl) :s15-s24.

[20]HIGASHI T, FRIEDMAN SL, HOSHIDA Y.Hepatic stellate cells as key target in liver fibrosis[J].Adv Drug Deliv Rev, 2017, 121:27-42.

[21]IKENAGA N, PENG ZW, VAID KA, et al.Selective targeting of lysyl oxidase-like 2 (LOXL2) suppresses hepatic fibrosis progression and accelerates its reversal[J].Gut, 2017, 66 (9) :1697-1708.

[22]LIU P, HU YY, LIU C, et al.Multicenter clinical study on Fuzhenghuayu capsule against liver fibrosis due to chronic hepatitis B[J].World J Gastroenterol, 2005, 11 (19) :2892-2899.

施引文献

资源附件(0)

访问统计